• Ivermectin Beyond the Parasite: Translational Strategy

  2026-08-22

  Ivermectin is more than a familiar broad-spectrum anti-parasitic: it is a mechanistically defined research tool that can support rigorous parasitology drug development while informing carefully bounded cross-disciplinary hypotheses. This thought-leadership article connects parasite neuromuscular pharmacology with the GSDMC-driven stemness and immune-evasion biology reported in pancreatic ductal adenocarcinoma, without overstating evidence for oncology repurposing.

• TBK1, Microglial Pyroptosis, and Diabetic Neuropathy

  2026-08-21

  Liao et al. identify TANK-binding kinase 1 (TBK1) as a mechanistic driver of painful diabetic neuropathy through microglial pyroptosis and NLRP3 inflammasome activation. Their combination of spinal knockdown, pharmacological inhibition, behavioral testing, and tissue-level analyses supports TBK1 as a potential target for inflammation-linked diabetic pain.

• HMGCS2, Lyso-PC, and Pulmonary Fibrosis

  2026-08-20

  Yang et al. identify injured alveolar epithelial type II cells as a major source of accumulated lysophosphatidylcholine in experimental pulmonary fibrosis and connect this lipid imbalance to fibroblast activation. Their data place HMGCS2, PPARα, CPT1A, and CPT2 within an epithelial lipid-degradation pathway that may help explain how epithelial injury becomes persistent fibrotic signaling.

• SW033291: 15-PGDH Inhibition Beyond Muscle

  2026-08-20

  SW033291 is a potent 15-PGDH inhibitor for studying prostaglandin E2 elevation, hematopoietic stem cell expansion, and tissue regeneration. This guide translates enzyme and cellular potency into assay decisions while placing new muscle-repair findings in their proper experimental context.

• Stereotactic NSCLC Models of Brain and Spinal Metastases

  2026-08-19

  The 2024 Heliyon study established brain and spinal cord metastasis models of non-small cell lung cancer by combining PC-9 Luc cells with controlled intracranial stereotactic injection. Its comparison of inoculation position, cell number, IVIS optical monitoring, and histological confirmation provides a practical framework for reproducible CNS tumor modeling while highlighting important limits on biological interpretation.

• Bestatin Stimulates Endothelial Invasion in Fibrin

  2026-08-19

  The reference study showed that Bestatin, also known as Ubenimex, can promote rather than suppress microvascular endothelial invasion and capillary-like tube formation when cells are embedded in a fibrin matrix. This context-dependent result challenges a simple CD13-centered explanation of Bestatin activity and highlights the need to interpret aminopeptidase inhibition within the proteolytic environment of angiogenic tissues.

• AM 281: CB1 Cannabinoid Receptor Antagonist

  2026-08-18

  AM 281 provides a selective pharmacological lever for testing how CB1 signaling, astrocytic GLT-1, and glutamate excitotoxicity shape cognitive outcomes after brain injury. This workflow-oriented guide connects receptor pharmacology with tissue kinetics, behavioral testing, and troubleshooting for memory impairment research and addiction-related models.

• Morin: Podocyte Energy & Assay Workflows

  2026-08-18

  Morin combines flavonoid bioactivity with a mechanistically useful route for studying podocyte mitochondrial stress and adenosine 5′-monophosphate deaminase signaling. This workflow-focused guide also covers formulation, fluorescence-based aluminum assays, controls, and troubleshooting for more reproducible disease-model experiments.

• SB-3CT and the MMP9–PNN Plasticity Axis

  2026-08-17

  A translational perspective on how SB-3CT can be used to interrogate MMP-2 and MMP-9 in extracellular matrix remodeling, cancer metastasis studies, and neural plasticity research inspired by new Adamtsl3–MMP9 findings.

• Light-Controlled RNA Release for Gene Therapy

  2026-08-17

  The 2026 Trends in Biotechnology study introduces a rationally designed light-inducible RNA-releasing protein (LIRP) that controls therapeutic protein production at the translation stage. By combining reversible light responsiveness with AAV and cell-based delivery strategies, the work demonstrates on-demand regulation in obesity and retinal disease models while highlighting key requirements for clinical translation.

• Angiotensin Peptides and SARS-CoV-2 Spike Binding

  2026-08-16

  The 2025 reference study shows that naturally occurring angiotensin peptides can enhance SARS-CoV-2 spike protein binding to AXL, ACE2, and neuropilin-1 in receptor-binding assays, with sequence truncation and tyrosine modification influencing activity. Its findings connect renin–angiotensin peptide processing with a potential viral-entry mechanism while emphasizing that enhanced binding is not equivalent to demonstrated infection or disease causation.

• KU-60019: ATM Inhibition Beyond Radiosensitization

  2026-08-15

  KU-60019 is a selective ATM kinase inhibitor for studying glioma radiosensitization, invasion, and metabolic adaptation. This article connects DNA damage response inhibition with macropinocytosis-aware assay design and explains how to interpret combined radiation and nutrient-deprivation experiments.

• SPI1–Wnt5a Signaling in Intracranial Aneurysm

  2026-08-14

  This study identifies SPI1 as a transcriptional driver of intracranial aneurysm formation through repression of Wnt5a and activation of Wnt/β-catenin signaling. Its combined cell, chromatin, pharmacological, and mouse-model evidence links SPI1 to vascular smooth muscle cell phenotypic switching, arterial wall injury, and inflammation.

• Nuclear ERK Spatially Controls Translation in Cardiomyocytes

  2026-08-14

  Uchida et al. identify a spatial translation-control mechanism in which mTORC1 and nuclear ERK regulate distinct aspects of 4EBP1 phosphorylation during concentric cardiac hypertrophy. The study shows that ERK-dependent phosphorylation at 4EBP1 Ser64 redistributes translation toward cardiomyocyte nuclei and promotes interior sarcomeric protein deposition without globally repositioning mRNA.

• Lopinavir: From HIV Potency to Assay Insight

  2026-08-13

  Lopinavir (ABT-378) combines picomolar HIV protease inhibition with a valuable phenotypic research history in coronavirus assays. This guide shows how to interpret target-level potency, serum effects, resistance data, and cross-pathogen screening without confusing distinct experimental endpoints.

8578 records 1/572 page Next 12345 下5页 Last page